| 08:00 - 09:15 | Abstract Session: Complications in transplantation |
202.a |
Post-transplantation diabetes: a rocky bridge from guidelines to the real-world Adnan Sharif, United Kingdom |
| 08:00 - 09:15 | Abstract Session: Pediatric transplant 1 |
204.a |
Immune monitoring by torque teno virus load in addition to virus-specific T cells after pediatric kidney transplantation Lars Pape, Germany |
| 10:40 - 12:10 | Abstract Session: Kidney Outcomes 1 |
220.a |
Polyomavirus perspective from a pathologies Binnaz Handan Ozdemir, Turkey |
| 10:40 - 12:10 | Abstract Session: HLA histocompatibility |
221.a |
Donor microvascular culture assay Medhat Askar, Qatar |
| 10:40 - 12:10 | Abstract Session: Advances in cell transplantation |
226.a |
Ethics in cell transplantation Marwan Masri, Lebanon |
| 10:40 - 12:10 | Abstract Session: Organ preservatiion, pre-conditioning and IRI |
228.a |
B-Cell and biomarkers Anita Chong, United States |
| 10:40 - 12:10 | Abstract Session: Sex & gender in transplantation |
229.a |
Impact of sex and microbiome on ABO antibodies Lori J. West, Canada |
| 13:40 - 15:10 | Abstract Session: Kidney Transplant Management Challenges 1 |
241.a |
Commercial kidney transplantation - social demographic challenges Huda Al-Taee, Iraq |
| 13:40 - 15:10 | Abstract Session: General infectious diseases 1 |
242.a |
RSV Vaccine Camille N. Kotton, United States |
| 13:40 - 15:10 | Abstract Session: Tackling global ethical issues in transplantation |
243.a |
What next for transplant ethics in the era of xenotransplantation? Dominique Martin, Australia |
243.7 |
Implementing a transparent, ethical and fair deceased donor allocation system in Thailand Adisorn Lumpaopong, Thailand |
| 13:40 - 15:10 | Abstract Session: Surgical and anesthesia issues: Through a donation lens-then societal factors |
246.a |
Technique to reduce IRI Henry Pleass, Australia |
| 13:40 - 15:10 | Abstract Session: Immune monitoring and Biomarkers |
247.a |
Novel biomarkers Jonathan Bromberg, United States |
| 13:40 - 15:10 | Abstract Session: Predictive model in transplantation |
249.a |
Predicting kidney allograft rejection using blood biomarkers Valentin Goutaudier, France |
| 16:50 - 18:30 | Abstract Session: Kidney: ABO incompatibility, HLA and Donor Characteristics |
| 260.a |
ABO-incompatible Living Kidney Transplantation Kazunari Tanabe, Japan |
| 16:50 - 18:30 | Abstract Session: Maximizing deceased donation |
261.a |
Overview of donation after medical assist in dying (MAID): The Canadian experience Matthew Weiss, Canada |
| 16:50 - 18:30 | Abstract Session: Lung Transplantation |
263.a |
Lung preservation technique Shaf Keshavjee, Canada |
| 16:50 - 18:30 | Abstract Session: Immunoregulation, tolerance and other topics |
265.a |
Infectious tolerance Megan Sykes, United States |
| 08:00 - 09:15 | Abstract Session: Liver complications & techniques |
301.a |
Surgical complications on liver Nancy L. Ascher, United States |
| 08:00 - 09:15 | Abstract Session: Transplant immunosuppression 2 |
302.a |
Immunosuppression in kidney Tx for children Esra Baskin, Turkey |
| 10:40 - 12:10 | Abstract Session: Kidney Transplant Management Challenges 2 |
320.a |
Underimmunosuppression as a major problem in kidney transplantation Caner Süsal, Turkey |
| 10:40 - 12:10 | Abstract Session: Biomarkers and immune monitoring |
| 321.a |
Tracking the effectors of allograft rejection Alexandra Sharland, Australia |
| 10:40 - 12:10 | Abstract Session: Heart transplantation |
326.a |
Heart Xenotransplantation Robert A Montgomery, United States |
| 10:40 - 12:10 | Abstract Session: Allocation and utilization |
328.a |
Challenges of starting a new decease transplant program in the Middle-East Mohamed Salah Eldin Zaki, Egypt |
328.b |
Maximizing deceased organ donation in the Middle-East Katayoun Najafizadeh, Iran |
| 13:40 - 15:10 | Abstract Session: General Infectious Diseases 2 |
342.a |
An emerging issue: Carbapenem resistant enterobacteriaceae in solid-organ tx Hande Arslan, Turkey |
342.b |
Beneficial impact of immunosuppressive and anti-retroviral regimens on outcomes following kidney transplantation in people living with HIV Peter G. Stock, United States |
| 13:40 - 15:10 | Abstract Session: Patient centered care in Tx |
347.a |
Putting patients at the heart of transplantation Lorna Marson, United Kingdom |
| 13:40 - 15:10 | Abstract Session: Cutting-edge of VCA transplantation |
346.a |
Setting up VCA and Uterus program Stefan G. Tullius, United States |
| 346.1 |
The world’s first combined face and whole-eye transplant: Technical aspects, surgical underpinnings, and 1-year outcomes Bruce E. Gelb, United States |
| 16:50 - 18:30 | Abstract Session: Pediatric transplant 2 |
365.a |
Chronic kidney disease in children in Syria Hala Wannous, Syrian Arab Republic |
| 08:00 - 09:15 | Abstract Session: Kidney Pre-Transplant Management |
|
Cardiac screening pre-transplant Steven J. Chadban, Australia |
| 08:00 - 09:15 | Abstract Session: Ethics in organ donation |
|
Improving deceased organ donation among muslim living globally Riadh A.S. Fadhil, Qatar |
| 08:00 - 09:15 | Abstract Session: Novel therapeutics and immunosuppression strategies 2 |
|
Microbiome modification for immune regulation Maria-Luisa Alegre, United States |
| 08:00 - 09:15 | Abstract Session: Kidney Transplant - Donor and Recipient Issues |
|
The US model of continuous distribution of donated organs: Better or worse Matthew Cooper, United States |
| 13:40 - 15:10 | Abstract Session: Kidney Outcomes and Complications 2 |
|
Rejection post-transplant Faissal Shaheen, Saudi Arabia |
| 13:40 - 15:10 | Abstract Session: Kidney Post-transplant Management Issues |
|
Updates on the management of post transplant anemia Mohammad Ghnaimat, Jordan |
| 13:40 - 15:10 | Abstract Session: Islet transplantation |
|
Fas pathway as an effective target for tolerance induction to pancreatic islet grafts Haval Shirwan, United States |